1996L0022 — EN — 14.10.2003 — 001.001 — 1
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
►B COUNCILDIRECTIVE96/22/EC
of29April1996
concerningtheprohibitionontheuseinstockfarmingofcertainsubstanceshavingahormonalor
thyrostaticaction andofbeta-agonists,andrepealingDirectives 81/602/EEC,88/146/EECand88/
299/EEC
(OJ L 125, 23.5.1996, p. 3)
Amended by:
Official Journal
No page date
►M1Directive 2003/74/EC of the European Parliament and of the Council of
22 September 2003L 262 17 14.10.2003
▼B
COUNCILDIRECTIVE96/22/EC
of29April1996
concerning the prohibition on the use in stockfarming of certain
substances having a hormonal or thyrostatic action and of beta-agonists, and repealing Directives 81/602/EEC, 88/146/EEC and
88/299/EEC
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty establishing the European Community, and
in particular Article 43 thereof,
Having regard to the proposal from the Commission (1),
Having regard to the opinion of the European Parliament (2),
Having regard to the opinion of the Economic and Social
Committee (3),
(1)Whereas Directive 81/602/EEC (4) prohibits certain substances
having a hormonal action and any substances having a thyro-static action and whereas Directive 88/146/EEC (
5) prohibits the
use in stockfarming of certain substances having a hormonal
action, whilst conceding derogations;
(2)Whereas Council Directive 88/299/EEC (6) lays down the condi-
tions for applying the derogations provided for in Article 7 ofDirective 88/146/EEC from the prohibition on trade in certain
categories of animals and their meat;
(3)Whereas, on account of the residues they leave in meat and other
foodstuffs of animal origin, certain substances having a thyro-static, oestrogenic, androgenic or gestagenic action may be
dangerous for consumers and may also affect the quality of
foodstuffs of animal origin;
(4)hereas new substances having an anabolizing action such asbeta-agonists are used illegally in livestock-rearing witha viewto stimulating the growth and yield of animals;
(5)Whereas the results of an enquiry conducted by the Commissionin the Member States from 1990 to 1992 show that beta-agonistsare widely available in the livestock-rearing sector, leading totheir illegal use;
(6)Whereas the improper use of beta-agonists can be a serious riskto human health; whereas, in the interests of the consumer, theholding, administering to animals of any species and the placingon the market for that purpose of beta-agonists should be prohib-
ited; whereas, moreover, the holding, administering to animals of
any species and the placing on the market of stilbenes and thyro-static substances should be prohibited and the use of othersubstances regulated;
(7)Whereas, however, the administering of medicinal products
based on beta-agonists may be authorized for well-defined ther-
apeutic purposes, in the case of certain categories of bovineanimals, equidaeand pets;
(8)Whereas, moreover, it is necessary to ensure that all consumers
are able to acquire meat and foodstuffs derived therefrom under
the same conditions of supply and that those products correspondas closely as possible to their concerns and expectations;1996L0022 — EN — 14.10.2003 — 001.001 — 2
(1) OJ No C 302, 9. 11. 1993, p. 8 and OJ No C 222, 10. 8. 1994, p. 16.
(2) OJ No C 128, 9. 5. 1994, p. 107.
(3) OJ No C 52, 19. 2. 1994, p. 30.
(4) OJ No L 222, 7. 8. 1981, p. 32. Directive as amended by Directive 85/358/
EEC (OJ No L 191, 23. 7. 1985, p. 46).
(5) OJ No L 70, 16. 3. 1988, p. 16. Directive as amended by the 1994 Act of
Accession.
(6) OJ No L 128, 21. 5. 1988, p. 36.
▼B
whereas, given consumer sensitivity, this can only bring about an
increase in the consumption of the products in question;
(9)Whereas the prohibition on the use of hormonal substances forfattening purposes should continue to apply; whereas the use ofcertain substances for therapeutic or zootechnical purposes maybe authorized but must be strictly controlled in order to preventany misuse;
(10)Whereas withdrawal periods are not harmonized at Community
level and there are considerable differences between Member
States, particularly as regards authorized veterinary medicinalproducts containing hormonal substances or beta-agonists;whereas, in the interests of harmonization, maximum withdrawalperiods should therefore be set for such medicinal products;
(11)Whereas, furthermore, live animals so treated for therapeutic or
zootechnical purposes and the meat from such animals should
not as a general rule be traded, since this could impair the effec-tiveness of the control arrangements of the scheme as a whole;whereas, however, derogations from the prohibition may, subjectto certain conditions, be provided for in respect of intra-Commu-
nity trade and imports from third countries of animals intended
for breeding and breeding animals at the end of their reproduc-tive life;
(12)Whereas such derogations may be authorized where adequateguarantees are provided so as to prevent distortion of trade;whereas such guarantees must cover the products which may be
used, the conditions governing their use and the checks to ensure
that the conditions are complied with, particularly with regard tothe necessary withdrawal period;
(13)Whereas provision should be made for the effective verificationof application of the provisions deriving from this Directive;
(14)Whereas Directives 81/602/EEC, 88/146/EEC and 88/299/EECshould be repealed;
(15)Whereas, if the illegal use of growth and productivity promotersin stockfarming is to be combated effectively in all MemberStates, action will have to be organized at Community level;
(16)Whereas, on 18 January 1996, the European Parliament asked
the Commission and the Council to continue opposing the
importation into the Community of meat treated with hormones,requested the maintenance of the total ban on the use of growthpromoters in stockfarming and, to that end, asked the Council toadopt without delay the Commission proposal on which the
European Parliament had delivered its opinion on 19 April 1994,
HAS ADOPTED THIS DIRECTIVE:
Article 1
1. For the purposes of this Directive, the definitions of meat and
meat products given in Directives 64/433/EEC (1), 71/118/EEC (2), 77/
99/EEC (3), and 91/495/EEC (4), the definitions of aquaculture products
given in Directive 91/493/EEC (5) and the definitions of veterinary1996L0022 — EN — 14.10.2003 — 001.001 — 3
(1) OJ No 121, 29. 7. 1964, p. 2012/64. Directive as last amended by Directive
95/23/EC (OJ No L 243, 11. 10. 1995, p. 7).
(2) OJ No L 55, 8. 3. 1971, p. 23. Directive as last amended by the 1994 Act of
Accession.
(3) OJ No L 26, 31. 1. 1977, p. 85. Directive as last amended by Directive 85/
68/EC (OJ No L 332, 30. 12. 1995, p. 10).
(4) OJ No L 268, 24. 9. 1991, p. 41. Directive as last amended by the 1994 Act
of Accession.
(5) OJ No L 268, 24. 9. 1991, p. 15. Directive as last amended by Directive 95/
71/EC (OJ No L 332, 30. 12. 1995, p. 40).
▼B
medicinal products given in Directives 81/851/EEC (1) and 81/852/
EEC (2) shall apply.
2. In addition, the following definitions shall apply:
(a) ‘farm animals’ shall mean domestic animals of the bovine, porcine,
ovine and caprine species, domestic solipeds, poultry and rabbits,
as well as wild animals of those species and wild ruminants which
have been raised on a holding;
(b) ‘therapeutic treatment’ shall mean the administering — under
Article 4 of this Directive — to an individual farm animal of an
authorized substance to treat, after examination by a veterinarian,
a fertility problem — including the termination of unwanted gesta-tion — and, in the case of beta-agonists, to induce tocolysis incows when calving and to treat respiratory problems and to inducetocolysis in equidaeraised for purposes other than meat production;
(c) ‘zootechnical treatment’ shall mean the administering:
(i) to an individual farm animal of any substance authorized under
Article 5 of this Directive for synchronizing oestrus andpreparing donors and recipients for the implantation of
embryos, after examination of the animal by a veterinarian or,
in accordance with the second paragraph of Article 5, under hisresponsibility;
(ii) in the case of aquaculture animals, to a group of breeding
animals for sex inversion, on a veterinarian's prescription andunder his responsibility;
(d) ‘illegal treatment’ shall mean the use of unauthorized substances or
products or the use of substances or products authorized under
Community legislation for purposes or under conditions other thanthose laid down in Community legislation.
Article 2
Member States shall prohibit:
(a) the placing on the market of the substances listed in Annex II, list
A, for administering to animals of all species;
(b) the placing on the market of the substances listed in Annex II, list
B, for administering to animals, the flesh and products of which are
intended for human consumption, for purposes other than thoseprovided for in point 2 of Article 4 and in Article 5a.
Article 3
Member States shall prohibit, for substances listed in Annex II, and
shall provisionally prohibit, for substances listed in Annex III:
(a) the administering of those substances to farm or aquaculture
animals, by any means whatsoever;
(b) — the holding, except under official control, of animals referred to
in point (a) on a farm, and
— the placing on the market or the slaughter for human consump-
tion of farm animals,
which contain the substances referred to in Annex II and Annex III
or in which the presence of such substances has been established,unless proof can be given that the animals in question have beentreated in accordance withArticles 4, 5 or 5a;
(c) the placing on the market for human consumption of aquaculture
animals to which substances referred to above have been adminis-tered and of processed products derived from suchanimals;1996L0022 — EN — 14.10.2003 — 001.001 — 4
(1) OJ No L 317, 6. 11. 1981, p. 1. Directive as last amended by Directive 93/
40/EEC (OJ No L 214, 24. 8. 1993, p. 31).
(2) OJ No L 317, 6. 11. 1981, p. 16. Directive as last amended by Directive 93/
40/EEC (OJ No L 214, 24. 8. 1993, p. 31).▼M1
▼M1
(d) the placing on the market of meat from animals referred to in point
(b);
(e) the processing of the meat referred to in (d).
Article 4
Notwithstanding Articles 2 and 3, Member States may authorize:1. the administering to farm animals, for therapeutic purposes, of
►
M1 ◄testosterone and progesterone and deriva-
tives which readily yield the parent compound on hydrolysis afterabsorption at the site of application. Veterinary medicinal products
used for therapeutic treatment must comply with the requirements
for placing on the market laid down in Directive 81/851/EEC andbe administered only by a veterinarian, by injection or for the treat-ment of ovarian dysfunction in the form of vaginal spirals, but notby implant, to farm animals which have been clearly identified.
Treatment of identified animals must be registered by the veteri-
narian responsible. The latter must record at least the followingdetails in a register, which may be the one provided for in Directive81/851/EEC:
— type of treatment,
— the type of products authorized,— the date of treatment,
— the identity of the animals treated.
The register must be made available to the competent authority at its
request;
2. the administering for therapeutic purposes of authorized veterinary
medicinal products containing:
(i) allyl trenbolone, administered orally, or beta-agonists to equidae
and pets, provided they are used in accordance with the manu-
facturer's instructions;
(ii) beta-agonists, in the form of an injection to induce tocolysis in
cows when calving.
Suchsubstances must be administered by a veterinarian or, in th e
case of the veterinary medicinal products referred to in (i), underhis direct responsibility; treatment must be registered by the veteri-narian responsible, who shall record at least the details referred to inpoint 1.
Farmers shall be prohibited from holding veterinary medicinal
products containing beta-agonists which may be used for inductionpurposes in the treatment of tocolysis.
However, without prejudice to the first subparagraph of point 2 (ii),
therapeutic treatment of production animals, including breedinganimals at the end of their reproductive life, shall be prohibited.
Article 5
►
M1Notwithstanding Article 3(a) and without prejudice to Article 2,
Member States may authorise the administering to farm animals, forthe purpose of zootechnical treatment, of veterinary medicinal productshaving an oestrogenic (other than oestradiol 17 βand its ester-like deri-
vatives), androgenic or gestagenic action which are authorised in
accordance withDirective 2001/82/EC of th e European Parliament
and of the Council of 6 November 2001 on the Community coderelating to veterinary medicinal products (
1).◄Suchveterinary medic-
inal products must be administered by a veterinarian to clearlyidentified animals; the treatment must be recorded by the veterinarianresponsible in accordance withpoint 1 of Article 4.
However, Member States may allow the synchronization of oestrus and
the preparation of donors and recipients for the implantation of1996L0022 — EN — 14.10.2003 — 001.001 — 5
(1) OJ L 311, 28.11.2001, p. 1.▼B
▼B
embryos to be effected not by the veterinarian direct, but under his
responsibility.
Withregard to aquaculture animals young fishmay be treated for th e
first three months for the purpose of sex inversion with veterinarymedicinal products that have an androgenous action and are authorizedin accordance withDirectives 81/851/EEC and 81/852/EEC.
In the cases provided for in this Article, the veterinarian shall make out
a non-renewable prescription, specifying the treatment in question and
the quantity of the product required and shall record the products
prescribed.
However, zootechnical treatment of production animals, including
during the fattening period for breeding animals at the end of theirreproductive life, shall be prohibited.
Article 5a
1. Notwithstanding Article 3(a) and without prejudice to Articles 2
and 11a, Member States may authorise the administering to farmanimals of veterinary medicinal products containing oestradiol 17 βor
its ester-like derivatives for:
— the treatment of foetus maceration or mummification in cattle, or
— the treatment of pyometra in cattle,
in accordance withDirective 2001/82/EC.
2. Notwithstanding Article 3(a) and without prejudice to Article 2,
Member States may authorise the administering to farm animals ofveterinary medicinal products containing oestradiol 17 βor its ester-
like derivatives for oestrus induction in cattle, horses, sheep or goatsuntil 14 October 2006, in accordance withDirective 2001/82/EC.
3. The treatment must be carried out by the veterinarian himself or
herself on farm animals which have been clearly identified. This treat-ment must be registered by the veterinarian responsible. The latter mustrecord at least the following details in a register, which may be thatprovided for in Directive 2001/82/EC:
— the type of product administered,
— the nature of the treatment,— the date of treatment,— the identity of the animals treated,— the date of expiry of the withdrawal period.
The register must be made available to the competent authority at its
request.
Stockfarmers shall be prohibited from holding on their farms veterinary
medicinal products containing oestradiol 17 βor its ester-like deriva-
tives.
Article 6
1. Hormonal products and beta-agonists the administration of which
to farm animals is authorised in accordance with Articles 4, 5 or 5a
must meet the requirements of Directive 2001/82/EC.
2. The following may not, however, be authorized in accordance
withparagraph1:
(a) the following hormonal products:
(i) products acting as a deposit;
(ii) products with a withdrawal period of more than 15 days after
the end of treatment;1996L0022 — EN — 14.10.2003 — 001.001 — 6
▼M1
▼B
▼M1
▼B
▼B
(iii) products:
— which were authorized under rules that preceded the
amendment made by Regulation (EEC) No 2309/93 (1),
— whose conditions of use are not known,
— for which no reagents or equipment exist for use in the
analytical techniques for detecting the presence of residuesin excess of the permitted limits,
(b) veterinary medicinal products containing beta-agonists which have
a withdrawal period of more than 28 days after the end of treat-
ment.
Article 7
1. For the purpose of trade, Member States may authorise the
placing on the market of animals for breeding and breeding animals at
the end of their reproductive life which, during the latter period, have
undergone a treatment referred to in Articles 4, 5 or 5a and mayauthorise the affixing of the Community stamp to meat from suchanimals where the conditions laid down in Articles 4, 5 or 5a and thewithdrawal periods provided for in the authorisation to place on themarket are complied with.
However, trade in high-value horses, and in particular racehorses,
competition horses, circus horses or horses intended for stud purposes
or for exhibitions, including registered equidaeto which veterinary
medicinal products containing allyl trenbolone or beta-agonists havebeen administered for the purposes referred to in Article 4, may takeplace before the end of the withdrawal period, provided that the condi-tions governing administration are fulfilled and that the type and dateof treatment are entered on the certificate or passport accompanying
these animals.
2. Meat or products from animals to which substances having an
oestrogenic, androgenic or gestagenic action or beta-agonists have
been administered in accordance withth e dispensatory provisions ofthis Directive may not be placed on the market for human consumptionunless the animals in question have been treated with veterinary medic-inal products complying withth e requirements of Article 6 and in so
far as the withdrawal period laid down was observed before the
animals were slaughtered.
Article 8
Member States shall ensure that:
1. at the time of the import, manufacture, storage, distribution, sale and
use of the substances referred to in Articles 2 and 3, their possessionis restricted to the persons authorised by national legislation in
accordance withArticle 68 of Directive 2001/82/EC.
2. in addition to the checks provided for in the Directives governing
the placing on the market of the various products in question, theofficial checks provided for in Article 11 of Directive 96/23/EC (
2)
are carried out by the competent national authorities without prior
notice, witha view to ascertaining:
(a) the possession or presence of substances or products prohibited
under►M1Articles 2 and 3 ◄, intended to be administered to
animals for the purpose of fattening;
(b) the illegal treatment of animals;1996L0022 — EN — 14.10.2003 — 001.001 — 7
(1) OJ No L 214, 24. 8. 1993, p. 1.
(2) See p. 10 of this Official Journal.▼M1
▼B
▼M1
▼B
▼B
(c) failure to observe the withdrawal periods provided for in Article
6;
(d) failure to observe the restrictions on the use of certain
substances or products laid down in ►M1in Articles 4, 5 and
5a◄;
3. the tests for the presence of:
(a) the substances referred to in point 1 in animals, in the drinking
water of animals and in all places where animals are bred or
kept;
(b) residues of the aforementioned substances in live animals, their
excrement and body fluids and in animal tissues and products
are carried out in accordance withAnnexes III and IV to Directive
96/23/EC;
4. where the checks provided for in points 2 and 3 reveal:
(a) the presence of substances or products the use or possession of
which is prohibited, or the presence of residues of substances theadministering of which comes under the heading of illegal treat-ment, suchsubstances or products are confiscated, wh ile any
animals treated or the meat therefrom is placed under official
supervision until the requisite penalties have been applied;
(b) failure to comply withth e requirements of points 2 (b) and (c),
the competent authority takes appropriate measures consistent
with the gravity of the infringement.
Article 9
Without prejudice to Directive 81/851/EEC, undertakings buying or
producing substances having a thyrostatic, oestrogenic, androgenic orgestagenic action and beta-agonists, undertakings authorized in any
capacity to market suchsubstances and undertakings buying or produ-
cing pharmaceutical and veterinary medicinal products from suchsubstances shall be required to keep registers detailing, in chronologicalorder, quantities produced or acquired and those sold or used for theproduction of pharmaceutical and veterinary medicinal products and
the names of the persons to whom such quantities were sold or from
whom they were purchased.
The above information must be made available to the competent
authority at its request and, in the case of computerized records, inthe form of a printout.
Article 10
Where the results of checks carried out in a Member State show failure
to comply with the requirements of this Directive in the country oforigin of the animals or products, the competent authority of thatMember State shall have recourse to Council Directive 89/608/EEC of21 November 1989 on mutual assistance between the administrative
authorities of the Member States and cooperation between the latter
and the Commission to ensure the correct application of legislation onveterinary and zootechnical matters (
1).
Article 11
1. Third countries whose legislation authorizes the placing on the
market and administration of stilbenes, stilbene derivatives, their salts
and esters, or of thyrostatic substances for administering to animals ofall species may not appear on any of the lists of countries provided forunder Community legislation from which Member States are authorizedto import farm or aquaculture animals or meat or products obtainedfrom suchanimals.1996L0022 — EN — 14.10.2003 — 001.001 — 8
(1) OJ No L 351, 2. 12. 1989, p. 34.
▼B
2. Member States shall also prohibit the importation from third
countries on any of the lists referred to in paragraph 1 of:
(a) farm or aquaculture animals
(i) to which products or substances referred to in ►M1Annex II,
List A,◄have been administered by any means whatsoever;
(ii) to which substances referred to in Annex II, List B, and Annex
III have been administered, unless those substances were admi-nistered in compliance withth e provisions and requirementslaid down in Articles 4, 5, 5a and 7 and the withdrawal periodsallowed in international recommendations have been observed;
(b) meat or products obtained from animals the importation of which is
prohibited under point (a).
3. However, animals intended for breeding, breeding animals at the
end of their reproductive life, or meat therefrom, from third countriesmay be imported subject to their affording guarantees at least equiva-
lent to those laid down in this Directive, which have been established
in accordance withth e procedure laid down in Article 33 of Directive96/23/EC for the purpose of giving effect to Chapter V of that Direc-tive.
4. Checks on imports from third countries shall be carried out in
accordance withArticle 4 (2) (c) of Council Directive 91/496/EEC of15 July 1991 laying down the principles governing the organization ofveterinary checks on animals entering the Community from third coun-tries (
1) and Article 8 (2) of Council Directive 90/675/EEC of 10
December 1990 laying down the principles governing the organization
of veterinary checks on products entering the Community from third
countries (2).
Article 11a
The Commission shall present within two years from 14 October 2003
to the European Parliament and to the Council, a report on the avail-ability of alternative veterinary medicinal products to those containing
oestradiol 17 βor its ester-like derivatives for the treatment of foetus
maceration or mummification in cattle, and for the treatment ofpyometra in cattle, and present to them the following year any neces-sary proposals intending to replace these substances in due time.
Likewise, with regard to the substances listed in Annex III, the
Commission shall seek additional information, taking into accountrecent scientific data from all possible sources, and keep the measuresapplied under regular review witha view to timely presentation to th eEuropean Parliament and to the Council of any necessary proposals.
Article 12
The Council, acting by a qualified majority on a proposal from the
Commission, may adopt transitional measures necessary for the intro-duction of the arrangements provided for in this Directive.
Article 13
1. Directives 81/602/EEC, 88/146/EEC and 88/299/EEC are hereby
repealed as from 1 July 1997.1996L0022 — EN — 14.10.2003 — 001.001 — 9
(1) OJ No L 268, 24. 9. 1991, p. 56. Directive as last amended by Commission
Decision 95/157/EC (OJ No L 103, 6. 5. 1995, p. 40).
(2) OJ No L 373, 31. 12. 1990, p. 1. Directive as last amended by Directive 95/
52/EC (OJ No L 265, 8. 11. 1995, p. 16).▼M1
▼B
▼M1
▼B
▼B
2. References made to the repealed Directives shall be construed as
being made to this Directive and should be read in accordance with thecorrelation table in the Annex.
Article 14
1. Member States shall bring into force the laws, regulations and
administrative provisions, including any penalties, necessary to comply
withth is Directive on 1 July 1997, and, for beta-agonists, by 1 July1997 at the latest. They shall forthwith inform the Commission thereof.
When Member States adopt these measures, they shall contain a refer-
ence to this Directive or shall be accompanied by such reference on theoccasion of their official publication. The methods of making suchreference shall be laid down by Member States.
2. Member States shall communicate to the Commission the text of
the main provisions of national law which they adopt in the field
governed by this Directive.
3. Pending application of the provisions of this Directive as regards
beta-agonists, the relevant national rules shall continue to apply incompliance with the general provisions of the Treaty.
Article 14a
Notwithstanding Articles 3 and 5a, and without prejudice to Article 2,
farm animals for which it can be certified that they have been adminis-
tered oestradiol 17 βor its ester-like derivatives for therapeutic or
zootechnical purposes prior to 14 October 2004 shall be subject to thesame provisions as those laid down for the substances authorised inaccordance withArticle 4(1) as regards th erapeutic use and Article 5as regards zootechnical use.
Article 15
This Directive shall enter into force on the day of its publication in the
Official Journal of the European Communities .
Article 16
This Directive is addressed to the Member States.1996L0022 — EN — 14.10.2003 — 001.001 — 10
▼M1
▼B
▼M1
ANNEX I
Correlationtable
This Directive Directives 81/602/EEC, 88/146/EEC and 88/299/EEC
Article 1 (1) Article 1 (1) 81/602/EEC
Article 1 (1) 88/146/EEC
Article 1 (2) (a) and (b) Article 1 (2) 81/602/EEC
Article 1 (2) 88/146/EEC
Article 2 (1) (b) 88/299/EEC
Article 2 (a) Article 3 81/602/EECArticle 2 (b) —
Article 3 Article 2 81/602/EEC
Article 4 (1) Article 4 81/602/EEC
Article 2 and Article 3 (b) 88/146/EEC
Article 2 (1) (a) and (2) (4) 88/299/EEC
Article 4 (2) —
Article 5 Article 4 81/602/EEC
Article 2 (1) (b) and (2) (4) 88/299/EEC
Article 6 Article 2 (3) 88/299/EEC
Article 7 (1) Article 7 88/146/EEC
Article 2 and 3 88/299/EEC
Article 7 (2) Article 4 88/299/EEC
Article 8 Article 7 81/602/EECArticle 9 Article 4 88/146/EECArticle 10 —Article 11 (1) —
Article 11 (2) Article 6 (1) and 6 (2) 88/146/EEC
Article 11 (3) Article 5 88/299/EECArticle 11 (4) Article 6 (7) 88/146/EECArticle 12 —
Article 13 —
Article 14 —Article 15 —1996L0022 — EN — 14.10.2003 — 001.001 — 11
▼B
▼B
This Directive Directives 81/602/EEC, 88/146/EEC and 88/299/EEC
Article 16 —
Annex —1996L0022 — EN — 14.10.2003 — 001.001 — 12
▼M1
ANNEX II
List of prohibited substances:
List A:
— thyrostatic substances
— stilbenes, stilbene derivatives, their salts and esters
List B:
— oestradiol 17 βand its ester-like derivatives
— beta-agonists1996L0022 — EN — 14.10.2003 — 001.001 — 13
▼M1
ANNEX III
List of provisionally prohibited substances:
substances having oestrogenic (other than oestradiol 17 βand its ester-like deri-
vatives), androgenic or gestagenic action.1996L0022 — EN — 14.10.2003 — 001.001 — 14